

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY DOMINICAN REPUBLIC	2. DATE OF BIRTH			2a. AGE 10 Years	3. SEX Male	3a. WEIGHT Unk	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year				Day	Month	Year	
			PRIVACY					14	JUL	2025	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)
The Pen did not work, it did not let her insert the medication [Device defective]

Case Description: This is a spontaneous report received from a Consumer or other non-HCP and a Nurse, from product quality group, Program ID: 164974.

A 10-year-old male patient received somatotropin (GENOTROPIN PEN), since Jul2025 (Batch/Lot number: unknown) at 1.4 mg 1x/day. The patient's relevant medical history and concomitant medications were not reported.

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Genotropin Pen (SOMATROPIN) Solution for injection #2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 1.4 mg, 1x/day #2)	16. ROUTE(S) OF ADMINISTRATION #1) Unknown #2) Unknown	
17. INDICATION(S) FOR USE #1) Unknown #2) Unknown		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) JUL-2025 / Unknown #2) Unknown	19. THERAPY DURATION #1) Unknown #2) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA		26. REMARKS
	24b. MFR CONTROL NO. PV202500086135	
24c. DATE RECEIVED BY MANUFACTURER 01-AUG-2025	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT 06-AUG-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	
		25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.

06-Aug-2025 17:29

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

The following information was reported: DEVICE DEFECTIVE (non-serious) with onset 14Jul2025, outcome "unknown", described as "The Pen did not work, it did not let her insert the medication".

The reporter considered "The Pen did not work; it did not let her insert the medication" not related to somatropin. Causality for "The Pen did not work, it did not let her insert the medication" was determined associated to device constituent of somatropin (malfunction).

Product Quality Group provided investigational results on 01Aug2025 for somatropin (device constituent): Manufacturing site investigation: No further investigation was required as no valid lot number or returned sample was available. This complaint will continue to be trended. If additional information becomes available, this complaint will be reopened. Device Investigation: This investigation is based on the information captured in the Complaint Description and Argus Report. The Complaint Issue "Loss of Function" was selected as the device did not work and did not let her apply the medication. Since the issue with the pen is not clear, the reported issue will be interpreted as Loss of function. The Risk Management File was reviewed to confirm that the Hazard(s) and Hazardous Situation(s) associated with the Complaint Issue are documented in the Hazard Analysis (document INX100281795, version 9.0). All complaint investigations are trended. There is no current trend alert documented.

Additional information: The patient's mother reported that she began Genotropin treatment last week, in Jul2025. On 14Jul2025, when she changed the medication inside the Pen, the Pen did not work, and it did not let her insert the medication. As of 16Jul2025, the nurse reported that there was an improper handling of the device by the patient's mother.

Batch/lot number is not provided, and it cannot be obtained.

Follow-up (16Jul2025): This is a spontaneous follow-up report received from a Nurse. Updated information: New reporter. Dosage regimen, new event.

Follow-up (01Aug2025): This is a follow-up report from product quality group providing investigation results. Updated information: Somatropin start date. The event "Device issue" was re-coded to "Device defective". Onset date of event added. The event "Wrong technique in device usage process" was removed.